Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“ASH Highlights 2026 – Advances in Thrombotic Thrombocytopenic Purpura (TTP)
One of the most impactful sessions today focused on emerging therapeutic strategies in immune TTP (iTTP) and congenital TTP (cTTP), particularly CD38-targeted therapy and recombinant ADAMTS13 replacement.
Daratumumab in Immune TTP (iTTP)
Data from the international, multicenter DarTTP study demonstrated:
- Rapid ADAMTS13 remission in 75% of patients with iTTP who were refractory or intolerant to rituximab and other immunosuppressive therapies
- Sustained remission (>6 months) in approximately two-thirds of responders
- Targeting CD38+ plasma cells offers a promising strategy in cases where B-cell depletion alone is insufficient
These findings represent an important advancement in the management of refractory iTTP and provide renewed hope for patients at high risk of relapse.
Congenital TTP (cTTP)
The session also highlighted a clinical case discussion and phase 3 data on recombinant ADAMTS13 (rADAMTS13) replacement therapy:
- Demonstrated favorable efficacy and safety profile
- Approved in the US, EU, and Japan for both prophylactic and on-demand use
- Represents a paradigm shift in long-term cTTP management, reducing dependence on plasma infusions
This lecture clearly underscored that TTP treatment is entering a new era of mechanism-based and targeted therapy.
Integrating these advances into national practice remains crucial, particularly with regard to laboratory capacity, ADAMTS13 monitoring, and access to innovative therapeutics in our region.”
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke